Results 171 to 180 of about 19,804 (260)

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike, Yoko Irie, Yuji Doi, Ryosuke Kemmotsu, Moe Kusushita, Yasuna Sakai, Tomonori Okita, Hiroyuki Sho, Ryoko Inui, Yukiko Tabuchi, Tetsuyuki Yasuda   +10 more
wiley   +1 more source

Assessment of Knowledge and General Attitudes of Primary Care Physicians Toward Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Drugs in the Management of Type 2 Diabetes Mellitus in the Qassim Region. [PDF]

Cureus
Aljulajil F, Rabbani U.
europepmc   +1 more source

Waist‐to‐height ratio and renal dysfunction as independent correlates of low handgrip strength in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen, Chen‐Kai Chou, Shao‐Wen Weng, Jung‐Fu Chen, Feng‐Chih Shen   +4 more
wiley   +1 more source

Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. [PDF]

Diabetes Obes Metab
Kaku K, Shimoda M, Osonoi T, Iwamoto M, Kaneto H.   +4 more
europepmc   +1 more source

Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub‐cohort iDIAMOND study

Journal of Diabetes Investigation, EarlyView.
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori, Kasei Ko, Satoko Notomi, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Saeko Osawa, Tsunehiko Yamamoto, Akio Kuroda, Munehide Matsuhisa   +12 more
wiley   +1 more source

Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats. [PDF]

Drug Des Devel Ther
Chayah M, Luque-González A, Gómez-Pérez V, Salagre D, Al-Shdaifat A, Campos JM, Conejo-García A, Agil A.   +7 more
europepmc   +1 more source

USP30 inhibits wound healing in diabetic foot ulcers by promoting TRAF6‐induced ferroptosis and angiogenesis inhibition

Journal of Diabetes Investigation, EarlyView.
High glucose upregulates USP30 in HUVECs, which deubiquitinates and stabilizes TRAF6. Stabilized TRAF6 suppresses GPX4 and SLC7A11, increases ROS/MDA/lipid peroxidation, and activates ferroptosis and apoptosis, leading to impaired angiogenesis and delayed wound healing.
Jingjing Yuan, Shuang Sui, Zhenghua Yang, Kaiwen Zhang, Qiang Hu   +4 more
wiley   +1 more source

Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study. [PDF]

Diabetes Metab Syndr Obes
Itsukaichi A, Yoshikawa F, Fuchigami A, Iwata Y, Sato G, Miyagi M, Hirose T, Uchino H.   +7 more
europepmc   +1 more source

DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient. [PDF]

Intern Med, 2020
Usami J, Takezawa Y.
europepmc   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source